The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

Patients with diabetes are at higher risk of cardiovascular diseases and cognitive
impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin …

Recent clinical trial data suggest a cardiorenal protective effect of sodium glucose
cotransporter 2 (SGLT2) inhibition. We demonstrate that chemical denervation in neurogenic …

Introduction: Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are recommended
after metformin for a large spectrum of patients with type 2 diabetes, because of a favorable …

Alzheimer's disease (AD) is a progressive neurodegenerative disease, characterized by
memory loss and multiple cognitive impairments. Genetic mutations cause a small …

Abstract Purpose of the Review Hyperactivity of sympathetic nervous system (SNS) plays a
role in the development of arterial hypertension and heart failure, two co-morbidities …

Among all physiologic functions of nitric oxide (NO) known so far, NO-dependent regulation
of vascular tone is one of the most important. Under physiological conditions vascular NO is …

Despite Sodium-glucose co-transporter-2 (SGLT2) inhibitors have been associated with a
reduced risk of heart failure in patients with type 2 diabetes mellitus (T2DM), the effect …

Context Mechanisms mediating the cardiovascular and renal protection exerted by SGLT2
inhibitors are still partially unknown. We investigated whether dapagliflozin modulates …

Hypertension is one of the most prevalent cardiovascular diseases worldwide. However, in
the population of resistant hypertension, blood pressure is difficult to control effectively …